RecruitingNCT06520787

DAta-driven personaLIzation of a digitAl Health Solution to Support Family Caregivers of Children With Chronic Conditions


Sponsor

Adhera Health, Inc.

Enrollment

40 participants

Start Date

Mar 11, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this feasibility study is to explore the needs of families with children with obesity and evaluate the impact of a combined intervention (children with obesity receiving pharmacological therapy in combination with the Adhera Caring Digital Program®) on treatment satisfaction, adherence, and mood. The main objectives are: * To evaluate the impact of the treatment combination (ACDP® and pharmacological treatment) in terms of satisfaction, engagement, adherence and mood, in families with children with obesity. * To better understand the educational and support needs of the families of children with obesity while under treatment and lifestyle changes. Participants will: * Use the Adhera Caring Digital Program® (ACDP®) for obesity, which includes digital therapeutic software, personalized messages, and educational materials. * Take pharmacological treatment as prescribed for one year. * Wear activity wristbands/watches to collect biometric data. * Attend monthly clinic visits for assessments and monitoring. * Complete psychometric questionnaires to measure satisfaction, adherence, and emotional outcomes. * Engage in chat-based communication and video conferencing with health coaches for support and monitoring.


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Caregivers of children between 13 and 18 years who are diagnosed with obesity and undergoing treatment according to the approved label by AEMPS1 (adolescents with obesity aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex).
  • Families of children with obesity who have been under pharmacological treatment before screening. This includes treatment with any of the following medications orlistat, metformin, liraglutide, semaglutide.
  • Participants who are willing to join ACDP® for 10 months and can interact with a smartphone during that time.
  • The family is willing to complement the pharmacological obesity treatment with a digital intervention.
  • Participants (patients and their caregivers) must be willing to use wearables for the entire length of the study.
  • Parents previously using a wearable will agree not to use it during the length of the study, as their wearable account must be synched to the patient's device. Further, they may need to agree on changing the account data for height, weight, and gender in their Google account.

Exclusion Criteria3

  • Families not fluent in Spanish.
  • Families of children with obesity and comorbidities.
  • Families of children with secondary causes of obesity (i.e., hypothalamic, genetic or endocrine causes).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

COMBINATION_PRODUCTACDP® and pharmacological treatment for obesity

40 Families of children with obesity that are already undergoing treatment and are willing to join a combined intervention. After the recruitment, the family will join Adhera Caring Digital Program® for 10 months. The combined intervention (digital and pharmacological intervention) will last one year, and there will be a 2-month follow-up. During the whole study (12 months, from recruiting to the end of follow-up) participants will wear a smartwatch (Fitbit or similar).


Locations(1)

Hospital Universitario Miguel Servet

Zaragoza, Aragon, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06520787


Related Trials